HLB Life Science Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 40,285.8 million compared to KRW 13,725.3 million a year ago. Net income was KRW 11,469.17 million compared to KRW 47,335.03 million a year ago. Basic earnings per share from continuing operations was KRW 113.1503 compared to KRW 478.274 a year ago. Diluted earnings per share from continuing operations was KRW 113.1503 compared to KRW 478.274 a year ago. Basic earnings per share was KRW 113.1503 compared to KRW 478.274 a year ago.
For the nine months, sales was KRW 471.06 million compared to KRW 617.45 million a year ago. Net income was KRW 7,696.4 million compared to KRW 15,244.6 million a year ago. Basic earnings per share from continuing operations was KRW 76.0674 compared to KRW 154.0366 a year ago. Diluted earnings per share from continuing operations was KRW 76.0674 compared to KRW 154.0366 a year ago. Basic earnings per share was KRW 76.0674 compared to KRW 154.0366 a year ago.